Investigations
Company investigations
We track public telehealth and compounder cases drawn from news investigations, federal and state actions, and manufacturer litigation. Each hub summarizes why the case matters, what is on the public record, and how this desk uses it for pattern context — not as a claim that we personally ran every probe. Submit a complaint about any company; deeper briefs stay behind the partner desk.
Journalists and advocacy groups: Investigative partners login for the findings desk.
Tracked public cases
Public-record investigations and litigation peers this desk monitors. Not every case is a Telehealth Transparency primary probe — see each hub for how we use it.
EllieMD
TrackedCash-pay telehealth marketing compounded GLP-1s and peptides, with a Brand Partner / MLM layer — and research-grade peptides offered for human consumption.
Mochi / Aequita
TrackedKING 5 “$elling $kinny” series on telehealth weight-loss drugs and Aequita Pharmacy — state inspection, Immediate Jeopardy finding, and halt of GLP-1 compounding at the supplier.
Zappy / Ousia
TrackedNPR pharmaceuticals reporting: sterile compounding tied to a telehealth brand without the sterile authority patients assumed — followed by license relinquishment under scrutiny.
MEDVi
TrackedBusiness Insider on Meta ads using AI / fabricated “doctor” personas; FDA warning letter on compounder identity and GLP-1 brand-equivalence claims — company says the cited site was an affiliate.
Henry Meds
TrackedNamed defendant in Eli Lilly’s 2025 false-advertising / compounded GLP-1 telehealth litigation cluster — part of brand-name manufacturer pushback against compounder marketing.
Fella
TrackedMen’s telehealth brand named in Eli Lilly’s 2025 compounded GLP-1 litigation cluster alongside other cash-pay compounder platforms.
Willow
TrackedTelehealth compounder named with peers in Eli Lilly’s 2025 false-advertising / compounded GLP-1 enforcement cluster.
Hims
TrackedNational DTC telehealth scale-up; public reporting on HHS→DOJ referral path involving oral compounded semaglutide — an agency-escalation case study.